Bio-Rad Third-Quarter 2026 Earnings Results Conference Call and Webcast - BIO-RAD LABORATORIES INC

Explicit Guidance:

• FY2026 Currency-Neutral Revenue Growth: Reaffirmed at -3% to +0.5%, expected to finish near the midpoint.
• FY2026 Segment Revenue Growth (Currency-Neutral): Life Science segment projected at -3% to -1%; Clinical Diagnostics projected at -3% to +1%.
• FY2026 Q4 Revenue Growth: Expects a sequential ramp of 5–6% on a reported basis (Q3 to Q4).
• FY2026 Non-GAAP Gross Margin: Projected in the upper half of the 53%–54% range; anticipates a sequential decline in Q4 due to product mix shift toward instruments, sequential process chromatography revenue decline, and higher fuel costs expected to persist into 2027.
• FY2026 Q4 Operating Expenses: SG&A expected to be flat to Q3; R&D expected to step up by $3 million sequentially; approximately $40 million depreciation and amortization expected.
• FY2026 Non-GAAP Operating Margin: Projected in the upper half of the 10%–12% range.
• FY2026 Free Cash Flow: Reaffirmed full-year estimate of $290–$340 million; Q4 is seasonally the strongest period.
• Tariff Refunds: Any refunds received will be recognized on a GAAP basis only (excluded from non-GAAP results) and will not be passed to customers; expected to impact year-end 2026 results.

Business-Segment Outlook:

• Diagnostics: Returned to growth in Q3 2026; growth expected to be driven by Quality Systems and Diabetes products. Quality Controls remains a market leader with global strength; Diabetes growth is broad-based.
• Life Science – DDPCR: Remains a "durable growth driver" with instrument revenue growing >20% for three consecutive quarters; driven by conversions from qPCR and competitive wins. Long-term penetration remains low across biopharma R&D, clinical diagnostics, and applied testing.
• Life Science – Process Chromatography: Revenue improved sequentially throughout 2026; expects a sequential decline in Q4 2026 but year-over-year improvement for the full year 2026.
• Life Science – Academic/Government (US): Conditions remain challenging; no recovery assumed for Q4 2026. NIH outlays declined ~15% in Q3 2026; federal fiscal year funding finished ~$6B below appropriations.
• China (APAC): Returned to growth in Q3 2026 (driven by order timing and favorable prior year). Future growth faces pricing pressure from National Healthcare Security Administration guidelines, with an estimated revenue impact of "middle single-digit millions" in 2027.
• MEA (EMEA): Logistics costs remain elevated; planning assumes continued supply chain disruption into 2027.
• Pull-through Rate: Consecutive improvement noted; however, pull-through has not yet normalized and is expected to continue through 2027 as installed systems ramp to full utilization.

Market and Competitive Outlook:

• Biopharma: Signs of improving customer activity and gradual recovery; expected to be constructive for demand over coming years. Shift noted from late-stage development to more discovery roles.
• Academic/US Government: Continued pressure anticipated; no recovery expected in Q4 2026.
• China Competitive Landscape: Continued preferences for domestic suppliers and pricing pressure remain; addressing via commercial execution and portfolio management.
• PAMA (US): Preliminary lab reimbursement rates published Sept 2026; final rates expected Nov 2026. No meaningful change in customer purchasing behavior observed to date; limited indirect impact expected on Bio-Rad business in 2027.
• AI Demand: Positive trend anticipated as customers transition from in silico modeling to wet lab work, increasing demand for reagents and product utilization.
• Supply Chain: Logistics costs elevated in MEA; continued disruption expected into 2027.

Macro / Industry Outlook:

• 2027 Revenue Growth: Management aims for "positive growth rate" in 2027, balancing lingering headwinds with innovation and portfolio management; specific 2027 guidance to be provided at the year-end call.
• Academic Spending: Potential tailwinds may arise from the midterm election results (impact on 2027–2028 outlook).
• China Regulations: National Healthcare Security Administration guidelines creating pricing pressure; final rollout assessments ongoing with potential for additional impact beyond the initial estimate.
• Macro Environment: Continued pricing pressure in China; elevated logistics costs in MEA.

Strategic Initiatives:

• Restructuring: Executing on a program with $30–$35 million in net annual savings; actions to take hold in late 2026 and 2027, with full realization expected by 2028.
• Cost Structure & Margins: Goal to deliver operating margins above 20% in the long term; committed to improving profitability while investing in innovation.
• Innovation/Product Launches: Launched ChemiDot Pro imaging system (Western blot) in Q3 2026 (accelerated by two quarters via R&D prioritization); expanded Foresight Pro portfolio with Renuvia resins. Aim for a consistent, predictable cadence of innovation.
• AI Integration: Deploying AI to improve operational productivity/decision-making and to enhance product capabilities (e.g., ChemiDot Pro algorithm).
• Capital Allocation:
  • M&A: Not seeking transformative deals; targeting $100–$500 million revenue acquisitions in DX or Life Science tools that drive differentiation and margin expansion.
  • Share Repurchases: Opportunistic rather than systematic; current view remains stock is undervalued.
  • Sartorius AG Stake: Maintained as a monetizable asset; no change in strategy to monetize if a scenario becomes favorable.
• Board Composition: Actively evaluating candidates to expand board with broader operational experience; updates expected in the near future.
• Elliott Management: Dialogue remains active and productive with alignment on objectives.

Risks and Headwinds to Outlook:

• Demand Weakness: Continued softness in US academic and government end markets; slow recovery in biopharma.
• Pricing Pressure: China regulations and domestic supplier preferences impacting pricing in the IVD market.
• Supply Chain Disruption: Elevated logistics costs and continued disruptions in MEA expected through 2027.
• Regulatory Impact: Final PAMA reimbursement rates may indirectly influence customer economics in 2027.
• Currency Volatility: 2026 guidance incorporates currency neutral assumptions, but FX impacts remain a variable.
• Product Mix: Sequential Q4 margin decline expected due to shift toward instruments (lower margin than consumables) and higher fuel costs.
• Pull-Through Normalization: Risk that consumable pull-through does not normalize as quickly as expected due to system utilization lag.

Management Tone on the Future:

• Confidence Level: Cautiously optimistic. Management expresses encouragement regarding progress in DDPCR, gross margin expansion, and innovation, but acknowledges "uneven" end markets.
• Outlook on 2027: Focused on driving "positive growth" and "further margin expansion," though starting conditions remain challenging.
• Strategic Conviction: Strong belief in the "durable growth driver" potential of DDPCR and the ability to exceed current performance to reach >20% operating margins long-term.
• Caution: Explicitly notes that 2027 revenue growth will not be fully normalized immediately and that pricing pressures/regulatory changes in China require a "measured view" of the near-term outlook.

Miscellaneous:

• Non-GAAP Adjustments: Full-year 2026 non-GAAP results exclude impacts from tariff refunds (GAAP only) and equity value changes in Sartorius AG.
• Investor Relations: Management to attend UBS Global Healthcare Conference next week.